Thermo Fisher Scientific, Inc. (TMO)
Thermo Fisher Scientific, Inc. is a global leader in scientific research and laboratory equipment, providing innovative products and services for life sciences, healthcare, and applied markets. Founded in 2006 through the merger of Thermo Electron and Fisher Scientific, the company specializes in laboratory instrumentation, analytical instruments, reagents, and consumables used in various science and clinical applications. It supports research institutions, pharmaceutical companies, and government agencies with solutions that advance scientific discovery and improve health.
Dividend History
Investors can expect a dividend payout of $0.43 per share, scheduled to be distributed in 8 days on October 15, 2025
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| October 15, 2025 | $0.43 | 2025-09-15 | 2025-09-15 |
| July 15, 2025 | $0.43 | 2025-06-13 | 2025-06-13 |
| April 15, 2025 | $0.43 | 2025-03-14 | 2025-03-14 |
| January 15, 2025 | $0.39 | 2024-12-13 | 2024-12-13 |
| October 15, 2024 | $0.39 | 2024-09-13 | 2024-09-13 |
Dividends Summary
- Thermo Fisher Scientific, Inc. has issued 55 dividend payments over the past 13 years
- The most recent dividend was paid 84 days ago, on July 15, 2025
- The highest dividend payed out to investors during this period was $0.43 per share
- The average dividend paid during this period was $0.22 per share.
Company News
The global thyroid cancer diagnostics market is projected to grow from USD 3.27 billion in 2025 to USD 5.22 billion by 2034, with a 5.34% CAGR, driven by technological advances, increasing cancer awareness, and improved diagnostic techniques.
Thermo Fisher Scientific is issuing a four-part bond offering in the U.S. investment-grade market, with proceeds intended for general corporate purposes amid potential government shutdown concerns.
William Blair analyst Matt Larew initiated coverage of Thermo Fisher Scientific with an outperform rating, highlighting the company's competitive advantages and potential for recovery in the biopharma segment despite current market softness.
The article discusses research reports on Thermo Fisher Scientific, Micron Technology, and KLA. Thermo Fisher is benefiting from new product launches and strong financial performance, while Micron is seeing improved market conditions and rising demand for memory and storage. KLA is performing well due to strong wafer inspection business and AI ad...
The UK's competition regulator has cleared Thermo Fisher Scientific's $3.1 billion acquisition of Swedish biotech firm Olink Holding.
